TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma

NEXT STORY
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
PREV STORY
Scopus BioPharma Launches Duet Therapeutics
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation Studies

author_avatar
NASDAQ Market News

Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise

Second quarter revenue of $6.6 millionRecord biopharma demand in quarter with $7.1 million in ...

author_avatar
NASDAQ Market News

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

author_avatar
NASDAQ Market News